- Home
- CNC vs MRNA Comparison
CNC vs MRNA Comparison
Compare CNC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNC | MRNA |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1B | 26.7B |
| IPO Year | 2001 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CNC | MRNA |
|---|---|---|
| Price | $67.42 | $79.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 12 |
| Target Price | ★ $46.75 | $34.27 |
| AVG Volume (30 Days) | 4.0M | ★ 8.0M |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $194,777,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $8.31 | $9.36 |
| Revenue Next Year | $1.05 | $15.43 |
| P/E Ratio | $21.80 | ★ N/A |
| Revenue Growth | ★ 19.44 | 4.29 |
| 52 Week Low | $25.08 | $22.28 |
| 52 Week High | $69.29 | $81.40 |
Technical Indicators
Market Signals| Indicator | CNC | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 65.88 | 79.87 |
| Support Level | $33.27 | $45.69 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.17 | 5.44 |
| MACD | 0.03 | 2.10 |
| Stochastic Oscillator | 84.45 | 95.25 |
Price Performance
Historical ComparisonAbout CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.